Fulcrum Therapeutics Stock Forecast
NASDAQ: FULCHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
FULC analyst consensus
Consensus (5 analysts)
none
Avg. price target
$3.67-2.13%
- Strong buy 0
- Buy 0
- Hold 4
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 5 Wall Street analysts covering Fulcrum Therapeutics (2026-10-08), 0 rate the stock a buy or strong buy, 4 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $3.67, with a high estimate of $4.00 and a low estimate of $3.00. The average target implies downside of 2.1% from the current price of $3.75.
The spread between the highest and lowest targets is 33.3%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for FULC.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 0 | 0% |
| Hold | 4 | 80% |
| Sell | 0 | 0% |
| Strong sell | 1 | 20% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $3.00 | -20.00% |
| Average target | $3.67 | -2.13% |
| High target | $4.00 | +6.67% |